A PYMNTS Company

US: Johnson & Johnson announces $4.15B diagnostics sale

By  |  January 16, 2014

Pharmaceutical and self-care giant Johnson & Johnson announced with asset management firm The Carlyle Group a sale of J&J’s diagnostics unit in a deal made for $4.15 billion, say reports.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Johnson & Johnson will sell its Ortho-Clinical Diagnostics business to Carlyle, which deemed the purchase a reflection of the predicted growth of the diagnostics market and its evolving importance to clinical healthcare practices.

    The parties said they expect to close the deal mid-2014, though the acquisition remains subject to regulatory approval.

    The OCD business provides early screening and diagnostic services, among others.

    Full Content: Genetic Engineering & Biotechnoloty News

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.